Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

Temozolomide 17Magnetic Resonance Spectroscopy 16Radiotherapy 10Bevacizumab 7fluciclovine F-18 6Specimen Handling 6Topotecan 5Cyclophosphamide 5Biopsy 5fluorodopa F 18 4abemaciclib 4Vincristine 4Surgical Procedures, Operative 4Ketoconazole 4Irinotecan 4Fluorodeoxyglucose F18 4Ferrosoferric Oxide 4ribociclib 3gallium Ga 68 dotatate 3etoposide phosphate 3Radiation 3Pemetrexed 3Nivolumab 3Methotrexate 3Mesna 3Everolimus 3Etoposide 3Carboplatin 3posaconazole 2poly ICLC 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × eliglustat × CNS × Clear all
NCT07090538 2025-07-29

GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.

Chinese PLA General Hospital

Phase EARLY_PHASE1 Not yet recruiting
10 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡